Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer.

CONCLUSIONS: Hypermutated MMRd metastatic prostate cancer is associated with oncogene activation and subclonal diversity, which may contribute to a clinically aggressive disposition in selected patients. In patients with detectable ctDNA, cell-free DNA sequencing is a practical tool to prioritize this subtype for immunotherapy.
PMID: 31744831 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - November 18, 2019 Category: Cancer & Oncology Authors: Ritch E, Fu SYF, Herberts C, Wang G, Warner EW, Schönlau E, Taavitsainen S, Murtha AJ, Vandekerkhove G, Beja K, Loktionova Y, Khalaf D, Fazli L, Kushnir I, Ferrario C, Hotte S, Annala M, Chi KN, Wyatt AW Tags: Clin Cancer Res Source Type: research